MOUNTAIN VIEW, Calif., Oct 05, 2010 /PRNewswire via COMTEX/ --
IRIDEX Corporation (Nasdaq: IRIX) today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery devices. The EndoProbe is an intraocular laser delivery device used during vitreoretinal surgery for the treatment of multiple disorders including: diabetic retinopathy, retinal detachments and vitreous hemorrhage. IRIDEX distributes products in Japan through their partner, TOMEY Corporation.
"This approval represents another step in our global strategy of growing our disposable instrumentation product revenues," said Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX. "TOMEY has been an outstanding partner in selling our ophthalmic laser systems and delivery devices into the Japanese market. We are looking forward to the ramp-up and sales of these delivery devices."
The probes being introduced may be used with the current installed base of IRIDEX laser systems in Japan. "The EndoProbe product family includes single-use laser delivery devices with standard, shaped and specialized designs to complement each surgeon's personal technique," commented Eduardo Arias, SVP of International Sales and Business Development. "We expect sales of this expanded lineup of EndoProbe consumables in Japan will show positive incremental increases in the near future."
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to IRIDEX's statements relating to our disposable instrumentation products, our strategy relating thereto and our sales and revenues resulting from those products. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010, which was filed with the Securities and Exchange Commission on March 31, 2010 and our subsequent Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX
